We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing ALX148 as a foundational checkpoint immunotherapy

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, ALX148, will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology.

Latest News updated at 13:20:05 UTC

Oct 14, 2020

ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

Oct 06, 2020

ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board

Sep 22, 2020

ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer


ALX Oncology has announced that #ALX148 clinical results have been selected for presentation at #SITC2020 from November 11 – 14, 2020, 9:00am – 5:00pm ET: https://bit.ly/2FwF5U1 $ALXO

ALX Oncology names leading oncology experts Keith Flaherty, Charles M. Baum and Kipp Weiskopf to Scientific Advisory Board: https://bit.ly/36DWbuy

LifeSci Capital is hosting a KOL call on Wednesday, October 7, at 12:00 PM ET to discuss gastric/gastroesophageal junction cancer and the Phase 1 data with ALX Oncology’s CD47 inhibitor ALX148 plus trastuzumab in HER2+ patients. Register here: https://bit.ly/3cYJk78.

Load More...

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, ALX148, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.